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Available online 18 April 2016Shock and kill strategies involving the use of small molecules to induce viral transcription in resting CD4+T cells
(shock) followed by immune mediated clearance of the reactivated cells (kill), have been proposed as a method
of eliminating latently infected CD4+ T cells. The combination of the histone deacetylase (HDAC) inhibitor
romidepsin and protein kinase C (PKC) agonist bryostatin-1 is very effective at reversing latency in vitro. How-
ever, we found that primary HIV-1 speciﬁc CD8+ T cells were not able to eliminate autologous resting CD4+
T cells that had been reactivated with these drugs. We tested the hypothesis that the drugs affected primary
CD8+ T cell function and found that both agents had inhibitory effects on the suppressive capacity of HIV-
speciﬁc CD8+ T cells from patients who control viral replication without antiretroviral therapy (elite suppres-
sors/controllers). The inhibitory effect was additive and multi-factorial in nature. These inhibitory effects were
not seen with prostratin, another PKC agonist, either alone or in combination with JQ1, a bromodomain-
containing protein 4 inhibitor. Our results suggest that because of their adverse effects on primary CD8+ T
cells, some LRAs may cause immune-suppression and therefore should be used with caution in shock and kill
strategies.







CD8+ T cells1. Introduction
Latently infected CD4+ T cells are themajor barrier to HIV-1 cure ef-
forts. The cells contain integrated proviruses that are transcriptionally si-
lent and thus able to evade detection and clearance by the immune
system. The shock-and-kill cure strategy seeks toﬁrst reactivate these la-
tent viruses without causing global T cell activation followed by clear-
ance of the reactivated cells by the immune system (reviewed in
Siliciano and Siliciano, 2013; Archin and Margolis, 2014). Latency
reactivating agents (LRAs) are drugs that induceHIV-1 transcription. No-
table drug classes include PKC agonists and HDAC inhibitors (HDACi),
which have been very effective in inducing HIV-1 transcription in cell
lines (Contreras et al., 2009; Xing et al., 2011; Li et al., 2013;
DeChristopher et al., 2012). Unfortunately, in vitro experimentswith pri-
mary resting CD4 T cells frompatients on suppressive antiretroviral ther-
apy (ART) regimens suggest that most individual LRAs are unable to
induce substantive amounts of HIV-1 transcription with the notable ex-
ception of PKC agonists bryostatin-1-1 (Bullen et al., 2014) and ingenol
(Spivak et al., 2015). However, LRA combinations in the same systemnsHopkinsUniversity School of
21205, USA.
. This is an open access article underare capable of inducing signiﬁcant HIV-1 transcription (Laird et al.,
2015; Jiang et al., 2015; Darcis et al., 2015).
The other half of the cure strategy deals with killing newly
reactivated infected CD4+ T cells. Recent experiments suggest that re-
activation from latency is not enough to induce cell death (Shan et al.,
2012), and therefore there may be a need for immune mediated eradi-
cation. Expanded CD8+ T cell lines were able to clear reactivated la-
tently infected resting CD4+ T cells following exposure to the HDAC
inhibitor, vorinostat (Sung et al., 2015). However primary CD8+ T
cells from patients on suppressive ART regimens that were pre-
stimulated with overlapping Gag peptides were unable to consistently
reduce the amount of HIV-1 mRNA induced from autologous resting
CD4+ T cells that were activated with PMA and ionomycin (Walker-
Sperling et al., 2015).
The combination of romidepsin and bryostatin-1 has been shown to
be one of the best inducers of latent HIV-1 in primary CD4+ T cells
(Laird et al., 2015). However, bryostatin-1 has been showed to be in-
volved in the modulation of NFkB and NFAT (Williams et al., 2004)
and romidepsin is known to affect the function of NK cells and CD8+
T cells (Kelly-Sell et al., 2012; Jones et al., 2014). Other HDAC inhibitors
have furthermore been known to induce Treg cells in vitro (Akimova
et al., 2010; Tao et al., 2007). The immunomodulatory activity of the
two drug classes thought to be most promising in cure efforts thereforethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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reactivated latently infected CD4+ T cells.
In this study, we sought to determine the ability of HIV-speciﬁc
CD8+ T cells from patients with progressive HIV-1 disease on ART
(chronic progressors) to kill HIV-infected CD4+ T cells after treatment
with LRAs. To elucidate the contribution of the drug treatments theHIV-
speciﬁc response, suppression of infectionwas examinedwith elite sup-
pressor CD8+ T cells that had been pre-treated with different LRAs, in-
cluding an HDAC inhibitor, a bromodomain-containing protein 4
inhibitor, and multiple PKC agonists. Finally, we examined the mecha-
nisms that may have contributed to the effects of drug treatment on
CD8+ T cell function. Our results have implications for the HIV-1 cure
agenda.
2. Methods
2.1. Donor blood samples
HIV-1 positive and HIV-1 negative blood samples were obtained
from donors with written, informed consent and handled according to
a Johns Hopkins University IRB approved protocol. The chronic
progressors studied were HIV-1 positive individuals who were started
on suppressive ART therapy during chronic infection and have a viral
load of b20 copies of HIV RNA/mL. Elite suppressors are patients
who have maintained undetectable viral loads without antiretroviral
therapy. The clinical characteristics of the patients are summarized in
Table 1.
2.2. Primary cell isolations
PBMCswere obtained fromwhole blood via Ficoll-Paque PLUS gradi-
ent centrifugation (GE Healthcare Life Sciences). PBMCs underwent
negative selection for CD4+ T cells using the MACS system (CD4 Isola-
tion Kit, Miltenyi Biotech). Resting CD4+ T cells were further isolated
from the bulk population by depleting CD25+, CD69+, and HLA-
DR+ cells (CD25 microbeads, CD69 Isolation Kit, and HLA-DR
microbeads;Miltenyi Biotech).When applicable, CD8+T cells were ob-
tained via positive selection from PBMCs (CD8 microbeads, Miltenyi
Biotech) prior to any negative selection performed in experiments de-
scribed below.
2.3. Latency reactivation ex vivo and autologous suppression
Resting CD4+ T cells isolated from fresh blood samples from ART-
suppressed individuals as described above (“Primary Cell Isolation”)
were plated in 12-well plates with 5 × 106 (DeChristopher et al.,
2012) cells per replicate in non-stimulating media (RPMI
1640 + Glutamax, 10% FBS) and treated alone for six hours with theTable 1
Clinical characteristics of the chronic progressors studied.
Subject Current CD4+ T cell count Nadir CD4+ T cell count Tim
CP8 424 18 8 y
CP9 991 190 8 y
CP11 1032 177 8 y
CP 14 646 12 4 y
CP 16 921 203 5 y
CP25 584 NA 4 y
ES 3 1149 NA NA
ES 6 601 NA NA
ES 9 798 NA NA
ES 22 1033 NA NA
ES 24 1742 NA NA
ES 31 1236 NA NA
3TC: lamivudine, ABC: abacavir, FTC: emtricitabine, TDF: tenofovir, DTG: dolutegravir, EFV: e
darunavir.
NA: Not applicable.combination of bryostatin-1 (B, 10 nM; Sigma Aldrich) and romidepsin
(R, 40 nM; Selleck Chemicals) in the presence of efavirenz (EFV, 10 μM)
and raltegravir (RAL, 4 μM) to prevent new infection and more closely
mimic in vivo conditions. CD8+ T cells were isolated at this time as de-
scribed above from PBMCs that had been previously stimulated for
seven days in the presence of 100 U IL-2/mL and overlapping consensus
Gag and Nef peptides (10 μg/mL; AIDS Reagent Database). At the con-
clusion of the six hours, the pre-stimulated CD8+ T cells were co-
cultured with the resting CD4+ T cells at a 1:1 effector:target ratio
and concentration of 5 × 106 (DeChristopher et al., 2012) cells/mL for
another 18h in the presence of B/R, EFV, and RAL at the same concentra-
tion as the initial treatment. The CD8+ T cells were not washed prior to
co-culturewith resting CD4+T cells. In a second set of experiments, the
CD8+ and CD4+ T cells were co-cultured together for 24 h in the pres-
ence of B/R, EFV, and RAL. For each replicate, at the conclusion of the full
24 h, supernatant samples and the full 5 × 106 (DeChristopher et al.,
2012) cell samples were harvested and placed in TRIzol LS and TRIzol
(Life Technologies), respectively, for the isolation of supernatant and
cell-associated RNA.
2.4. Isolation and quantiﬁcation of cell-associated and supernatant HIV-1
mRNA
Cell-associated and supernatant RNA were isolated, and the HIV-1
mRNA present in those samples was then quantiﬁed as previously de-
scribed (Bullen et al., 2014; Laird et al., 2015; Walker-Sperling et al.,
2015). Supernatant RNA samples were measured on a Roche
LightCycler 480 Real-Time PCR thermocycler with TaqMan Fast Ad-
vanced Mastermix (Applied Biosystems) run as per manufacturer's in-
structions and the following primers: Forward (5′→ 3′) CAGATGCTGC
ATATAAGCAGCTG (9501–9523), Reverse (5′→ 3′) TTTTTTTTTTTTTTTT
TTTTTTTTGAAGCAC (9629-poly A). The probe used is as follows:
(5′→ 3′) FAM-CCTGTACTGGGTCTCTCTGG-MGB (9531–9550) (all nu-
cleotide coordinates relative to HXB2 consensus sequence). The molec-
ular standard curves used for the quantiﬁcation were generated using
serial dilutions of a TOPO plasmid containing the ﬁnal 352 nucleotides
of the HIV-1 genomic RNA with the addition of 30 deoxyadenosines
on the 5′ end to mimic the poly-A tail.
2.5. Latency reactivation agents' effects on autologous suppression of ex
vivo infection
Autologous bulk CD8+ and CD4+ T cells were freshly isolated from
PBMCs from elite suppressors as described above (“Primary Cell Isola-
tion”) for a modiﬁed version of a previously described HIV suppression
assay (Buckheit et al., 2012). CD8+ T cells were treated for six hours in
non-stimulating media (RPMI 1640 + Glutamax, 10% FBS) with either
nothing, DMSO, romidepsin (40 nM), JQ1 (1 μM; Sigma Aldrich),e on suppressive regimen Current regiment HLA-A HLA-B
ears 3TC, RAL EFV 1, 68 57, 58
ears TDF, FTC, DRV/c 34, 68 58, 81
ears TDF, FTC, DRV/r 2, 11 25, 57
ears DRV/r, DTG
ears 3TC, ABC, DTG 29, 20 42, 81
ears TDF, FTC, RAL 3, 30 8, 42
NA 25, 68 51, 57
NA 23 15, 57
NA 2, 30 27, 57
NA 30, 31 15, 57
NA 24, 30 7, 57
NA 3 27, 58
favirenz, RAL: raltegravir, DRV/c: cobicistat boosted darunavir, DRV/r: ritonavir boosted
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centrations (10 nM, 1 nM, 0.1 nM), or prostratin at two concentrations
(1 μM, 0.3 μM; Sigma Aldrich) alone or in the combinations of
romidepsin and bryostatin-1, romidepsin and prostratin, or
bryostatin-1 and JQ1 at those concentrations. Meanwhile, the bulk
CD4+ T cells were spinoculated at 1200 ×g for two hours at 37 °C
with HIV-1NL4 − 3 ΔEnv − GFP, a replication incompetent lab strain
pseudovirus with env replaced with gfp and whose expression is con-
trolled by the HIV promoter. At the conclusion of the six-hour drug
treatments, the drug was washed from the CD8+ T cells before the
cells were added in a 1:1 effector:target ratio to the spinoculated
CD4+ T cells. The cells co-cultured in nonstimulating media (RPMI
1640 + Glutamax, 10% FBS) were incubated for three days prior to
FACS analysis.
2.6. Bryostatin-1 treatment and its effects on cytokine production
PBMCs isolated from elite suppressors were plated at a concentra-
tion of 1 × 106 (DeChristopher et al., 2012) cells permL in 48-well plates
and treated for six hours with nothing, DMSO, romidepsin (40 nM),
bryostatin-1 (10 nM), and the combination of romidepsin and
bryostatin-1. After treatment, cells were washed and then re-plated as
before in non-stimulating media (RPMI 1640 + Glutamax, 10% FBS).
All samples were cultured with Golgi Plug and Golgi Stop (BD Biosci-
ences) as per manufacturer's instructions and 1 μg/mL of anti-CD28
and anti-CD49d antibodies (NA/LE anti-CD28 clone CD28.2, anti-
CD49d clone 9F10; BD Biosciences). The no-stimulation control had no
additional treatment added, and the two stimulation conditions were
incubated with 10 μg/mL overlapping consensus Gag peptides and
1 μg/mL anti-CD3 for stimulation (NA/LE anti-CD3 clone HIT3a; BD Bio-
sciences), respectively.
2.7. General effects of latency reactivation agents on immune markers and
cell death
PBMCs isolated fromHIV-negative donor bloodwere plated at a con-
centration of 1 × 106 (DeChristopher et al., 2012) cells permL in 48-well
plates and treated for six hours with nothing, DMSO, romidepsin
(40 nM), bryostatin-1 at three concentrations (10 nM, 1 nM, 0.1 nM),
prostratin (0.3 μM), and the combination of romidepsin (40 nM) and
bryostatin-1 (10 nM). The doses of these drugs were selected based
on the concentrations needed to reverse latency either alone or in com-
bination (Laird et al., 2015). 40 nM of romidepsin is below the concen-
tration of the plasma levels achieved in patients treated with this drug
for lymphoma (Wei et al., 2014). Plasma bryostatin-1 levels of close to
1 nM have been achieved in patients receiving the highest tolerated
dose of the drug (Smith et al., 2011). Two sets of cultures were set
aside for analysis by FACS at six hours post-treatment and 18 hours
post-treatment. For the rest of the cultures, cells were washed after
six hours of drug treatment prior to replating in fresh plates at the
same concentration of cells in non-stimulating media (RPMI
1640 + Glutamax, 10% FBS) either in the presence or absence of
1 μg/mL anti-CD3/CD28 antibodies (NA/LE anti-CD3 clone HIT3a, anti-
CD28 clone CD28.2; BD Biosciences) for an additional 1, 2, or 3 days be-
fore FACS analysis.
2.8. FACS analysis of suppression and immune markers
For the suppression experiments, samples were analyzed for in-
fected CD4+ T cells by staining for CD3 (PacBlue, BD Biosciences),
CD4 (BV605, Biolegend), and CD8 (APC-H7, BD Biosciences) and exam-
ining for theGFP+(pseudovirus infected) cells. The amount of suppres-
sion was calculated by comparing the amount of infected CD4+ T cells
with CD8+ T cell co-culture to those without effector cell co-culture (%
Suppression = [1 − (% GFP+ CD4+ T cells cultured with CD8+ T
cells) / (% GFP+ CD4+ T cells without effectors)] × 100%). Intracellularcytokine expression was determined with the following panel:
CD3·PacBlue, CD4·BV605, CD8·APC-H7, CD69·APC (Biolegend), IL-
2·PE (BD Biosciences), TNFα·PE-Cy7 (BD Biosciences), IFNγ·PerCP-
Cy5.5 (BD Biosciences), and Perforin-FITC (Cell Sciences). Immune
markers and cell death were examined in the HIV-negative donors'
cells via three staining panels (Panel A: CD3·APC-Cy7 [Biolegend],
CD4·BV605, CD8·APC [BD Biosciences], PD-1·FITC [Biolegend]; Panel
B: CD3·PE [BD Biosciences], CD4·BV605, CD8·APC-H7, CD69·APC, 7-
AAD [BD Biosciences], Annexin V·V450 [BD Biosciences]; Panel C:
CD3·PacBlue, CD8·APC-H7, CD69·BV605, CD160·PE [Biolegend], TIM-
3·PE-Cy7 [Biolegend], 2B4·APC [BD Biosciences]). CD69, the exhaustion
markers, and Annexin V expression are shown as raw data, but expres-
sion of CD3 is compared via MFI ratio (MFI ratio = [MFI of marker in
treatment]/[MFI of marker in no treatment]). All samples were run on
a BD FACSCantoII ﬂow cytometer and analyzed in FlowJo vX.0.7.
2.9. Statistics
Statistical analyses performed for HIV-1 RNA (Fig. 1) were con-
ducted using Wilcoxon matched-pair signed-rank test, the nonpara-
metric alternative to the paired t-test as previously described
(Walker-Sperling et al., 2015). Descriptive statistics for other experi-
ments are presented as means and standard deviations. Comparisons
of treatment groups to the control (NT) were conducted using repeated
measures ANOVAmodel with adjusted pair-wise comparisons to NT via
Dunnett's correction. Strength of evidence, threshold p-values, will be
presented as: ns (N0.05), * (b0.05), ** (b0.01), and *** (b0.001). Para-
metricmethods were used due to the failure of nonparametric to detect
signiﬁcance for paired data with sample size less than six. All statistics
and graphics were performed with GraphPad Prism 6.
3. Results
3.1. Ex vivo reactivation of latently infected CD4+ T Cells and CD8+ effec-
tor-mediated elimination
Resting CD4+ T cells from six ART-suppressed HIV-1+ individuals
were treated with 10 nM bryostatin-1 and 40 nM romidepsin (B/R)
for twenty-four hours to reactivate latent HIV-1 proviruses. A subset
of samples fromeach of the individualswas further co-culturedwith au-
tologous CD8+ T cells that had been previously cultured for 7 days in
the presence of IL-2 and overlapping consensus Gag and Nef peptides
to determine whether these immune effectors cells could eliminate la-
tently infected cells. In a prior study we demonstrated that viral release
occurred as early as 6 h after resting CD4+ T cell stimulation (Walker-
Sperling et al., 2015), so the CD8+T cells were added at 6 h tominimize
their exposure to the latency reversal agents. In all six individuals, cell-
associated HIVmRNAwas increased by amedian of 12.72-fold due to B/
R treatment as compared to resting CD4+ T cells cultured in the ab-
sence of drugs (p b 0.0002, Fig. 1B). However, the co-culture of B/R-
treated resting CD4+ T cells with stimulated CD8+ T cells did not re-
sult in a signiﬁcant decrease in the amount of HIV-1 mRNA, although
three of the six individuals showed a trend towards a decrease in the
amount of cell-associated HIV-1 mRNA (Fig. 1B). The effect of drugs
and CD8+ T cells on the release of virus into culture supernatant was
also examined. HIV-1 mRNA present in culture supernatant increased
signiﬁcantly from an undetectable baseline (500 copies/mL) following
B/R treatment to a median of 5281.6 copies/ml (p b 0.001), and there
was no signiﬁcant difference seen when the B/R-treated CD4+ T cells
were co-cultured with CD8+ T cells (Fig. 1C). Of the six individuals,
only CP25 had a decrease in both cell-associated and supernatant HIV-
1 mRNA due to co-culture of B/R-treated resting CD4+ T cells with
CD8+ T cells (Fig. 1C). We repeated the experiments with CD8+ T
cells present at the time point 0 to ensure that the failure to eliminate
reactivated CD4+ T cells was not due to early transcription and transla-
tion in the absence of the effector cells. However, there was still no
Fig. 1. Nef- and Gag-stimulated CD8+ T cells from chronic progressors are not capable of eliminating newly-reactivated autologous CD4+ T cells following bryostatin-1/romidepsin-
treatment. A) Schematic of methods. Blue arrows indicate methods common to both experiments, red arrows indicate methods for Fig. 1B and C, and green arrows indicate methods
for Fig. 1D and E. B) Level of cell-associated HIV-1 mRNA seen with no stimulation (NS), treatment with bryostatin-1/romidepsin (B/R) or treatment with B/R and co-culture with
CD8+ T cells for 18 h. No signiﬁcance is indicated by n.s., and the listed p-value indicates the level of signiﬁcance as determined by a Wilcoxon signed rank test for signiﬁcance.
C) Level of HIV-1 mRNA present in culture supernatant for 6-hour drug treatment followed by 18-hour CD8+ T cell co-culture. Dotted line indicates the level of detection (500 copies
HIV mRNA/mL). The listed p-value indicates the level of signiﬁcance as determined by a Wilcoxon signed rank test for signiﬁcance. D) Cell-associated HIV mRNA from 24-hour drug
treatment and CD8+ T cell co-culture with resting CD4+ T cells. The listed p-value indicates the level of signiﬁcance as determined by a Wilcoxon signed rank test for signiﬁcance.
E) Supernatant HIV mRNA from 24-hour drug treatment and CD8+ T cell co-culture with resting CD4+ T cells. The listed p-value indicates the level of signiﬁcance as determined by a
Wilcoxon signed rank test for signiﬁcance. Dotted line indicates the level of detection (100 copies HIV mRNA/mL). Mean ± standard error of 1–3 replicates is shown for each individual.
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mRNA expression (Fig. 1E) when the stimulated CD4+ T cells were
co-cultured with CD8+ T cells.
3.2. Elite suppressor CD8+ T cell responses after ex vivo treatment with la-
tency reactivating agents
To elucidate whether or not the lack of an effective response to
reactivated HIV-1 from latently infected CD4+ T cells in the chronic
progressors was due to host factors or the drugs themselves we studiedthe effects of the drugs onHIV-speciﬁc CD8+T cell responses. Elite sup-
pressors were used for these studies, as they are known to have qualita-
tively superior HIV-speciﬁc CD8+ T cell responses as compared to the
average chronic progressor (Betts et al., 2006; Migueles et al., 2002;
Sáez-Cirión et al., 2007; Migueles et al., 2008; Hersperger et al., 2010).
CD4+ T cells from ES were infected with replication incompetent
HIV-1NL4 − 3 ΔEnv − GFP pseudovirus and co-cultured with autologous
CD8+ T cells that had been previously incubated with a variety of la-
tency reversing agents (LRAs), as previously described (Buckheit et al.,
2012; Pohlmeyer et al., 2013). DMSO, the vehicle for all the drugs, had
Fig. 2. Elite suppressor CD8+ T cell responses are inhibited by bryostatin-1 and romidepsin alone and in combination. CD8+ T cells from 4 elite suppressors were preincubated with the
indicated LRAs for six hours prior to the addition to autologous CD4+ T cells infected with lab strain HIV-1 pseudovirus in a 1:1 effector:target ratio and the percent suppression of viral
replicationwas determined. Triplicateswere performed and themean values are shown for each individual. For panelsD and E, data from2 separate experimentswith cells fromES6, ES22,
and ES24 were averaged, and data from an additional elite suppressor was included. A) Comparison of bryostatin-1 and romidepsin treatments. B) Comparison of prostratin and
romidepsin treatments. C) Comparison of bryostatin-1 and JQ1 treatments. D) Comparison of prostratin and JQ1 treatment. E) Comparison of romidepsin and other HDAC inhibitors.
One-way repeated measures ANOVAs were used to determine signiﬁcance for each of the two sets of experiments. Symbols directly above treatments indicate differences from NT, no
treatment. * p b 0.05, ** p b 0.01, *** p b 0.001, **** p b 0.0001.
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treatment (Fig. 2A–E). Romidepsin (40 nM throughout) alone and
bryostatin-1 at either 10 nM or 1 nM signiﬁcantly inhibited the ability
of elite suppressor CD8 T cells to suppress infection as compared to un-
treated CD8+ T cells (Fig. 2A). The combination of romidepsin and all
three concentrations of bryostatin-1 tested (10 nM and 1 nM signiﬁ-
cantly inhibited suppression as compared to untreated CD8+ T cells,
and the combinations of romidepsin and bryostatin-1 at either 10 nM
or 1 nM were much more inhibitory than either drug alone, with an
81.8% and 84.0% reduction in the amount of suppression seen for the
combination of bryostatin at 10 nM and romidepsin from each drug
alone, respectively, and 72.6% and 70.8% reduction for the combination
of bryostatin at 10 nM and romidepsin from each alone.
In order to determine whether the inhibition of suppression is
unique to bryostatin-1 or is a feature of PKC agonists, CD8+ T cells
from elite suppressors were also treated with prostratin at either 1 μM
or 0.3 μM alone or in conjunction with romidepsin. As opposed to
bryostatin-1, prostratin alone at either concentration had no signiﬁcant
effect upon the suppressive capacity of the CD8+ T cells (Fig. 2B). The
combination of prostratin at 1 μM and 0.3 μMwith romidepsin signiﬁ-
cantly inhibited the suppression of infection (p b 0.0001), but this inhi-
bition was very similar to the inhibition seen by romidepsin alone (Fig.
2B).
The effect of JQ1, a bromodomain-containingprotein 4 inhibitor,was
also examined alone and in conjunction with bryostatin-1 or prostratin
as these combinations of drugs have also been shown to be effective at
reversing latency in vitro (Laird et al., 2015). Treatment of CD8+ T cellswith JQ1 (1 μM) alone resulted in a slight, nonsigniﬁcant decrease in
CD8+ T cell suppression (Fig. 2C). A signiﬁcant decrease in CD8+ T
cell-mediated suppression was seen when JQ1 was given in combina-
tion with bryostatin-1 at 10 nM and 1 nM (p b 0.001 for both), but
this was not signiﬁcantly different from the inhibition seen with
bryostatin-1 alone at either concentration (Fig. 2C). In contrast, the
combination of prostratin and JQ-1 did not have a signiﬁcant effect on
the CD8+ T cell function (Fig. 2D).
In order to determine whether romidepsin's effect on CD8+ T cell
suppressive activity was unique to this drug or a feature of all HDAC in-
hibitors, we compared the effects of romidepsin vorionostat and
panobinostat on ES CD8+ T cell function. The concentrations used
were based on concentrations that had been shown to be effective in
prior studies (Archin et al., 2012, Laird et al., 2015) and were similar
to levels that have been achieved in vivo (Wei et al., 2014; Rubin
et al., 2006; Archin et al., 2012, Bauer et al., 2014). While romidepsin
and panobinostat had signiﬁcant inhibitory effects on ES CD8+ T cells,
vorinostat did not cause signiﬁcant suppression (Fig. 2E). These results
are similar to results obtained with HIV-speciﬁc CD8+ T cell clones
(Jones et al., 2014).
3.3. CD8+ T cell cytokine production after LRA treatment
We next sought to ﬁnd a mechanism for the inhibition of suppres-
sion due to bryostatin-1 treatment and ﬁrst examined the ability of
elite suppressor HIV-speciﬁc CD8+ T cells to produce cytokines after
a 6-hour treatment with bryostatin-1 and romidepsin followed by 12-
Fig. 3. Production of IFN-γ, TNF-α, and IL-2 by CD8+ T cells increases with bryostatin-1 treatment. IFN-γ (A), TNF-α (B), simultaneous IFN-γ and TNF-α (C), and IL-2 (D) production in
unstimulated (NS), Gag-peptide stimulated, and anti-CD3/CD28 stimulated CD8+ T cells is shown for each of three elite suppressors with the mean ± standard error. Signiﬁcance was
determined via a series of one-way repeated measures ANOVAs examining each of the twelve conditions separately, and level of signiﬁcance indicated above a bar is in comparison to
no treatment from the same stimulation. * p b 0.05.
222 V.E. Walker-Sperling et al. / EBioMedicine 8 (2016) 217–229
Fig. 4.Bryostatin-1 and bryostatin-1/romidepsin combination treatments cause an increase in CD8+T cell death. Eight HIV negative donors' PBMCswere treatedwith LRAs and examined
for annexin V expression on CD8+ T cells. A) Annexin V expression in CD8+ T cells treated with drug for 6 h and then cultured for three days post-treatment in non-stimulating media.
B) Annexin V expression in CD8+ T cells treated with drug for 6 h and then stimulated with anti-CD3/CD28 for either one or two days afterward. C) Annexin V and 7-AAD expression in
CD8+ T cells treated with drug for 6 h and then stimulated with anti-CD3/CD28 for either one or two days afterward. One-way repeated measures ANOVAs were used to calculate
signiﬁcance, and the level of signiﬁcance indicated is in comparison to the no treatment condition. * p b 0.05, ** p b 0.01, *** p b 0.001, **** p b 0.0001.
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clonal antibodies. Bryostatin-1 treatment alone tended to cause an in-
crease in the percentage of cells that produced TNF-α, both TNF-α andIFN-γ, and IL-2 following anti-CD3/CD28 stimulation (for IL-2,
p b 0.05; Fig. 3B). In contrast, the B/R combination caused an increase
in the percentage of cytokine-producing CD8+ T cells at baseline
Fig. 5.Bryostatin-1 treatment induces an increase in exhaustionmarker expression inunstimulatedCD8+T cells. Eight HIV-negative donors' PBMCswere treatedwith LRAs and examined
for PD-1 expression on CD8+T cells, and four donors' PBMCswere examined for TIM-3, 2B4, and CD160 expression. A) PD-1 expression in CD8+T cells treatedwith drug for 6 h and then
incubated in non-stimulating media for an additional three days. B) TIM-3 expression. C) 2B4 expression. D) CD160 expression. The level of signiﬁcance indicated is in comparison to no
treatment. * p b 0.05, ** p b 0.01.
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Gag peptides (TNF-α; p b 0.05) and anti-CD3/CD28 monoclonal anti-
bodies (TNF-α, TNF-α and IFN-γ, and IL-2; for IL-2 only, p b 0.05).
Thus it appears that a decrease in cytokine expression was not the
mechanism of suppression of CD8+ T cell antiviral activity.
3.4. PKC agonist effects upon cell death and exhaustion in T cells
To further elucidate the mechanisms by which the LRAs affected
CD8+ T cell function, CD8+ T cells from HIV-negative donors were in-
terrogated for the amount of cell death induced by drug treatment as
determined by Annexin V expression. For both 6-hour and 18-hour
treatments with LRAs, the combination B/R treatment induced a trend
towards a higher amount of cell death than cells treated with DMSO
(not shown). To examine the effects of the LRAs on cell viability over
time, cells were treated for six hours before being washed and cultured
for an additional three days in the absence of stimulation. For this time
course, 10 nM bryostatin-1-treated CD8+ T cells had a trend towards
more cell death on day 1 and signiﬁcantly more on day 2 (p b 0.05). A
trend towards higher cell death was likewise observed in B/R-treated
CD8+ T cells (Fig. 4B). To model the effect of the LRAs on activated
CD8+ T cells, CD8+ T cells treated with 10 nM bryostatin-1 and B/R
for six hours were stimulated with anti-CD3/CD28 antibodies for an ad-
ditional two days. Cells treated with anti-CD3/CD28 generally had in-
creased cell death compared to CD8+ T cells that did not receive this
treatment, but only bryostatin-1 and B/R treatment of anti-CD3 acti-
vated cells caused a signiﬁcant increase in cell death compared toFig. 6. Bryostatin-1 treatment induces an increase in exhaustion marker expression in stimulate
for PD-1 expression on CD8+T cells, and four donors' PBMCswere examined for TIM-3, 2B4, an
incubatedwith anti-CD3/CD28 antibodies for an additional two days. B) 2B4 expression. C) CD1
no treatment. * p b 0.05, ** p b 0.01.antibody treatment alone as determined by annexin V expression
(Day 1, bryostatin-1: p b 0.05; Day 2, B/R: p b 0.05; Fig. 4B) and sup-
ported by trends with annexin V and 7-AAD co-expression.
We also examined the expression of the exhaustion markers PD-1,
Tim-3, 2B4, and CD160 following 6 h of treatment with the different
drugs as a potential cause of the observed inhibition of CD8+ T cell re-
sponses. Bryostatin-1 at 10 nM and B/R induced modest but signiﬁcant
increases in PD-1, TIM-3 and 2B4 expression at different time points
over a 3 day time period (example of PD-1 gating shown in Supplemen-
tary Fig. 1A; Fig. 5A–C). In order to determine the effects of the LRAs on
activated cells, we looked at the expression of these exhaustionmarkers
on cells that were exposed to drugs for 6 h and then stimulated with
CD3 and CD28 speciﬁc antibodies. PD-1, CD160 and 2B4 expression
levels were signiﬁcantly increased in activated cells that were treated
with bryostatin-1 or B/R on day 2 whereas romidepsin tended to in-
crease CD160 expression on the activated cells at the same time point
(Fig. 6A–C). Furthermore, bryostatin-1 also signiﬁcantly PD-1 expres-
sion in the stimulated cells on day 2 as measured by ratio of the mean
ﬂuorescence intensity of the treated cells to that of the untreated cells
(p b 0.05; Supplementary Fig. 1B).
In order to determine whether the expression of the exhaustion
markerswas just amarker of T cell activationwe looked at CD69 expres-
sion on CD8+ T cells treated with LRAs. Bryostatin-1 treatment has
been shown to induce CD69 on resting CD4+ T cells (Laird et al.,
2015), and we found very high levels of this early activation marker
on CD8+ T cells that were treated with 10 nM and 1 nM bryostatin-1,
B/R, and prostratin (Fig. 7). PD-1, 2B4 and TIM-3 expression was notd CD8+ T cells. Eight HIV-negative donors' PBMCswere treated with LRAs and examined
d CD160 expression. A) PD-1 expression in CD8+T cells treatedwith drug for 6 h and then
60 expression. D) TIM-3 expression. The level of signiﬁcance indicated is in comparison to
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Fig. 7. CD69 expression is upregulated due to treatment with PKC agonists. Eight HIV-
negative donors' PBMCs were treated with LRAs for 6 h before being washed and then
cultured in non-stimulating media for up to three days and examined for CD69
expression on CD8+ T cells. Mean expression ± standard error is indicated for each
treatment. Bryostatin-1 treatment at 10 nM and 1 nM and bryostatin-1 (10 nM)/
romidepsin treatment all signiﬁcantly upregulate CD69 for all four timepoints
(p b 0.0001), as did prostratin treatment (p b 0.001, p b 0.001, p b 0.01, and p b 0.05 at
the respective timepoints) as calculated bymultiple one-way repeatedmeasures ANOVAs.
226 V.E. Walker-Sperling et al. / EBioMedicine 8 (2016) 217–229upregulated on prostratin-treated cells, implying that the expression of
these exhaustion markers was not just a reﬂection of partial activation
although further experiments are needed to verify this.
3.5. PKC agonist-induced modulation of TCR-related markers
PKC agonists such as PMA have been known to downregulate CD3
(Salio et al., 1997), which has the potential to inhibit T cell responses.
In order to determine whether LRA treatment had an effect on CD3 ex-
pression, we examined the change in the mean ﬂuorescence intensity
(MFI) of this marker. CD8+ T cells treated with bryostatin-1 at 10 nM
and 1 nM and B/R had a signiﬁcant decrease in CD3 expression after
six hours of treatment (bryostatin-1: p b 0.01 at 10 nM, p b 0.05 at
1 nM; B/R: p b 0.01; Fig. 8A). However, after 18 h of treatment,
bryostatin-1 at 10 nM and 1 nM, the B/R combination, and prostratin
alone cause signiﬁcant decreases in CD3 expression compared to un-
treated cells (p b 0.0001 for 10 nM bryostatin-1 and B/R; p b 0.001 for
bryostatin-1 at 1 nM and prostratin; Fig. 8A). For CD8+ T cells treated
for six hours and then cultured for a day in the absence of treatment,
bryostatin-1 at 10 nM and 1 nM as well as B/R continued to cause a sig-
niﬁcant decrease in CD3 expression (bryostatin-1: p b 0.01, p b 0.05, re-
spectively; B/R: p b 0.001; Fig. 8B). Unlike bryostatin-1 treatment alone,
however, the effect of B/R on CD3 expression maintained at day 1 (Fig.
8A,B). Overall, while bryostatin-1 has an effect on CD3 expression
alone, the combination of bryostatin-1 with romidepsin causes both a
more severe and longer-lasting phenotype.
4. Discussion
Current HIV-1 cure strategies seek to eliminate the latent reservoir
by speciﬁcally activating HIV-1 so the immune system can clear the la-
tently infected cells. The most promising latency reactivating agent
(LRA) regimens in vitro thus far appear to be combinations of HDAC in-
hibitors (HDACi) and PKC agonists (Laird et al., 2015). However, some of
these drugs have previously been suggested to have immunomodula-
tory effects (Jones et al., 2014; reviewed in Akimova et al., 2012, and
Remoli et al., 2012). In this study, we conﬁrm that the combination of
bryostatin-1 and romidepsin is effective in reversing latency, however
we found that even following stimulation with high concentrations of
IL-2 and Gag and Nef consensus peptides, CD8+ T cells from fully sup-
pressed chronic progressors were unable to reduce the amount of HIV-1
mRNA associated with CD4+ T cells or prevent release of virions from
these cells in the context of bryostatin-1 and romidepsin treatment.
One limitation of our study is that we did not measure actual viral pro-
tein production or antigen presentation following latency reversal. It is
possible that some of the mRNA we measured is defective and did not
lead to the synthesis of functional proteins that could be recognized
by CD8+ T cells. Another possibility is that the effects of the LRAs
may be short lived in vivo since HIV-speciﬁc CD8+ T cells from patients
treated with vorinostat (Sung et al., 2015) and romidepsin (Søgaard
et al., 2015) appeared to be functional in ex vivo studies, but even a
short term effect could be important for viral clearance. Another limita-
tion is the relatively small number of patients studied in this
manuscript.
In a prior study, autologous ex vivo expanded virus-speciﬁc
cytototoxic T lymphocytes, but not unexpanded CD8+ T cells, from
HIV infected patients were able to signiﬁcantly reduce the number of la-
tently infected cells following reversal with vorinostat (Sung et al.,
2015). The discrepancy between that study and our ﬁndings could po-
tentially be explained by the fact that vorinostat has much less of an ef-
fect of on CD8+ T cells than did romidepsin, bryostatin-1 and the
combination of the 2 drugs. Chronic progressors' primary CD8+ T
cells are generally not effective in controlling HIV-1 replication
(reviewed inMigueles and Connors, 2015), whichmay also partially ac-
count for observed results. In order to determine other potential causes,we examined the effect of four separate LRAs alone and in combination
on the HIV-speciﬁc CD8+ T cell response of elite suppressors.
Elite suppressors are HIV-positive individuals who have viral loads
of b50 copies of HIV-1 RNA per milliliter in the absence of antiretroviral
therapy (O'Connell et al., 2009). These individuals are known to have
qualitatively superior HIV-speciﬁc CD8+ T cell responses than chronic
progressors (Betts et al., 2006; Migueles et al., 2002; Sáez-Cirión et al.,
2007;Migueles et al., 2008; Hersperger et al., 2010).We performed sup-
pression assayswith cells from four elite suppressors and found that un-
treated CD8+T cells were able to suppress infection effectively but that
treatment with romidepsin (40 nM) or bryostatin-1 (10 nM) alone sig-
niﬁcantly inhibited this suppression by nearly 50%. The combination of
the two LRAs at those concentrations fully ablated the suppression in
two individuals and otherwise signiﬁcantly reduced the average sup-
pression by 90% suggesting that the two drugs may have an additive,
negative effect (Fig. 2A). Interestingly, prostratin, another PKC agonist
did not have an inhibitory effect on CD8+ T cell mediated suppression,
suggesting that the effect on CD8+ T cell function may not be a feature
of the entire class of drugs. HDAC inhibitors such as romidepsin and
panobinostat have been shown to selectively cause the death of acti-
vated cells (Jones et al., 2014), and PKC agonists such as bryostatin-1,
prostratin, and PMA are known to cause partial activation in T cells
(Hess et al., 1988; Drexler et al., 1990; Scheid et al., 1994), with
bryostatin-1 speciﬁcally acting as a TLR-4 ligand (Ariza et al., 2011).
We therefore combined romidepsinwith prostratin,which also induced
partial activation as determined by CD69 expression, to determine if the
additive negative effect seen when bryostatin-1 and romidepsin were
combinedwas a general effect of adding an HDAC inhibitor to a PKC ag-
onist. Interestingly, the combination had an equal amount of suppres-
sion as romidepsin alone (Fig. 2B). JQ1 (1 μM), a bromodomain-
containing protein 4 inhibitor, also had minimal effect on CD8+ T cell
mediated suppression and did not appear to have an additive inhibitory
effect when it was combined with bryostatin-1. The combination of
prostratin and JQ1 has also recently shown to be effective (Laird et al.,
2015) and these drugs together did not have an adverse effect on
CD8+ T cell function.
In order to determine the mechanism for the inhibition of suppres-
sion seen with romidepsin, bryostatin-1, and the combination of the
two, we examined the LRA treatment-dependent toxicity and induction
of exhaustion on CD8+ T cells. Bryostatin-1 treatment at 10 nM causes
an increase in cell death and PD-1 expression, and combined bryostatin-
1 and romidepsin treatment more closely mimics the effects of
bryostatin-1 treatment as compared to romidepsin treatment, suggest-
ing that the phenomena are bryostatin-1-mediated. The increased cell
death and exhaustion shortly after treatment with 10 nM bryostatin-1
likely contributes to the CD8+ T cell dysfunction in the suppression
Fig. 8. CD3 expression is decreased due to treatment with bryostatin-1, prostratin, and the combination of bryostatin-1/romidepsin. Eight HIV-negative donors' PBMCswere treatedwith
LRAs for at least 6 h and examined for CD3 expression on CD8+T cells. A)Mean ﬂuorescence intensity (MFI) of CD3 expression in CD8+T cells treatedwith drug for 6 or 18 h normalized
to no treatment. One-way repeated measures ANOVAs were used to calculate signiﬁcance for 6-hour and 18-hour treatments separately. B) Mean ﬂuorescence intensity (MFI) of CD3
expression in CD8+ T cells treated with drug for 6 h and then incubated in non-stimulating media for one day afterward normalized to no treatment. A one-way repeated measures
ANOVA was used to calculate signiﬁcance. The level of signiﬁcance indicated is in comparison to vehicle (DMSO). * p b 0.05, ** p b 0.01, *** p b 0.001, **** p b 0.0001.
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occur within an hour (Migueles et al., 2008).
PKC agonists are known to downregulate CD3 (Salio et al., 1997) as
well as CD4 (Gulakowski et al., 1997; Kulkosky et al., 2001; Hezareh
et al., 2004; Warrilow et al., 2006). Downregulation of CD3-TCR com-
plexes as well as the coreceptors CD4 and CD8 may inhibit the ability
of effector T cells to respond to their cognate antigen, leading us to ex-
amine the expression of these markers in T cells. We found that
bryostatin-1 treatment caused transient downregulation of CD3 in
unstimulated CD8+ T cells, but treatment with bryostatin-1 and
romidepsin prolonged this effect. Even a transient effect may beimportant because we have previously shown that virion release from
latently infected CD4+ T cells may occur as early as 6 h after activation
(Walker-Sperling et al., 2015), and therefore a quick immune response
will be needed to eliminate reactivated CD4+ T cells.
In summary, we have shown that the HDACi/PKC agonist LRA com-
bination of bryostatin-1 and romidepsin causes marked inhibition of
the HIV-speciﬁc CD8+ T cell response, as do both drugs alone. The inhi-
bition of the T cell response by bryostatin-1 may be due an increase in T
cell death and exhaustion marker expression as well as a downregula-
tion of CD3, resulting in a decreased ability of T cells to respond to stim-
uli. The combination of romidepsin with bryostatin-1 furthermore
228 V.E. Walker-Sperling et al. / EBioMedicine 8 (2016) 217–229causes a more severe and possibly longer-lasting downregulation phe-
notype, potentially contributing to the more severe inhibition of the T
cell response. Any HIV-1 cure strategy involving LRA-based reactivation
will likely depend upon the immune response to eliminate any latently
infected cells, but given the range of negative effects the LRAs have upon
the immune response alone and in combination, each potential LRA
therapy should be examined for its broad effects on adaptive immunity
before use in the context of HIV-1 cure. Combinations of latency reversal
agents such as prostratin and JQ1 that together do not have signiﬁcant
effects on HIV-speciﬁc immune responses may be the most effective
candidates for the shock and kill approach to HIV-1 eradication.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.04.019.
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